search
Back to results

An Integrated Intervention of Computerized Cognitive Training and Physical Exercise in Virtual Reality for People With Alzheimer's Disease (JDome) (JDome)

Primary Purpose

Alzheimer Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Computerized cognitive training plus aerobic exercise with the JDome System
Computerized cognitive training plus aerobic exercise with standard exercise bike
Sponsored by
Istituto Nazionale di Ricovero e Cura per Anziani
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Alzheimer Disease focused on measuring Alzheimer Disease, virtual system, aerobic exercise, cognitive training, dementia, quality of life

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 65 and over;
  • Pre-existing diagnosis of Alzheimer's, in mild phase, according to the 2011 criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA);
  • Clinical Dementia Rating Scale CDR = 1;
  • Mini Mental State Examination MMSE > 19;
  • Functional Ambulation Categories FAC ≥4;
  • Tinetti scale ≥ 20;
  • Presence of a contact family caregiver
  • Reside at home

Exclusion Criteria:

  • Failure to meet the inclusion criteria
  • Sensory deficits not compensated by the use of prostheses
  • Psychological and behavioral disorders not compensated by drug treatment
  • Medical contraindication to moderate intensity aerobic exercise

Sites / Locations

  • Cognitive Disorders and Dementia (CDCD) -INRCA Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

JDome rehabilitation group

control group

Arm Description

Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with the JDome System

Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with standard exercise bike

Outcomes

Primary Outcome Measures

change in cognitive impairment
Mini-Mental State Examination was designed as a clinical method for grading cognitive impairment. The score ranges from 0 to 30: scores ≥ 24 indicate normality, between 18-23 indicate mild cognitive impairment, between 11-17 moderate cognitive deficits, scores ≤ 10 severe cognitive impairments. The reported score will be corrected according to age and education.
change in short and medium term memory
Alzheimer's Disease Assessment Scale (ADAS-cog) consists of 11 items that investigate: short and medium term memory, language, praxia (simple, constructive, ideational), temporal-spatial orientation. The score ranges from 0 (no cognitive impairment) to 70 (maximum cognitive impairment).

Secondary Outcome Measures

change in quality of life
Alzheimer's Disease scale (QoL-AD) includes 13 items that evaluate subjective (eg, perceived quality of life and psychological well-being) and objective (eg, behavioral competence and environment) components of the quality of life. Items are rated by subjects with dementia on a 4-point scale from 1 (poor) to 4 (excellent). Higher scores indicate a better quality of life.
change in physical performance
Short Physical Performance Battery (SPPB) is a short battery of tests designed to assess the function of the lower limbs. This scale consists of 3 different sections: balance assessment, evaluation of walking on 4 linear meters, evaluation of the ability to perform, for 5 consecutive times, the sit to stand from a chair, without using the upper limbs. The total scale score therefore has a range from 0 to 12. A total score below 10 indicates frailty and a high risk of disability and falls. The 1-point change in score from pre to post test is of clinical relevance.
change in signs and symptoms of major depression
Cornell Scale for Depression in dementia (CSDD) contains 19 items evaluating signs and symptoms of major depression in individuals with dementia. Each item is rated for severity on a scale from 0 (absent) to 2 (severe). The information is collected through clinical observation and through two semi-structured interviews: one addressed to the caregiver and one to the person with dementia. The total score, given by the sum of the 19 items, if lower than 6 indicates the absence of depressive symptoms, if higher than 10 it indicates a probable major depression and finally if higher than 18 it indicates the presence of major depression
change in neuropsychiatric disturbances
Neuropsychiatric Inventory (NPI) evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. A total NPI score and a total caregiver distress score are calculated. The total NPI score, which can range from 1 to 144, is the product of the frequency of manifestation and the severity of each disorder. Higher scores indicate more frequent and more severe behavioral problems

Full Information

First Posted
May 30, 2022
Last Updated
May 30, 2022
Sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Collaborators
Fondazione Cariverona, Italy
search

1. Study Identification

Unique Protocol Identification Number
NCT05402423
Brief Title
An Integrated Intervention of Computerized Cognitive Training and Physical Exercise in Virtual Reality for People With Alzheimer's Disease (JDome)
Acronym
JDome
Official Title
An Integrated Intervention of Computerized Cognitive Training and Physical Exercise in Virtual Reality for People With Alzheimer's Disease: the JDome Study Protocol
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
June 27, 2022 (Anticipated)
Primary Completion Date
June 26, 2023 (Anticipated)
Study Completion Date
June 26, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Collaborators
Fondazione Cariverona, Italy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
JDOME is a randomized controlled trial to test the effectiveness of a computerized cognitive training with the Brainer web platform and aerobic training with the JDOME system vs. a computerized cognitive training with the Brainer web platform and aerobic training with a standard exercise bike in subjects with Alzheimer's Disease at early stage. The JDome BikeAround is a tool that take people with dementia on a virtual bicycle tour along the paths of memories. It combines an exercise bike, a dome-shaped projector and Google Street View technology.
Detailed Description
JDOME study is designed as a randomized controlled trial to test the effectiveness of a training that combines the JDome virtual reality system for aerobic exercise with computerized cognitive training via tablet. The Experimental Group (EG) will receive computerized cognitive training with the Brainer web platform and aerobic training with the JDOME system (a tool that combines an exercise bike, a dome-shaped projector and Google Street View technology).The Control Group (CG) will receive computerized cognitive training with the Brainer web platform and aerobic training with a standard exercise bike. Assessment will be performed at the baseline (T0), at the end of intervention (after eight weeks -T1) and 12 weeks after the end of intervention (follow-up T2). The primary aim is to assess the stabilization of the global cognition of people with mild-stage Alzheimer's disease at the Mini-Mental State Examination (MMSE) and at the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog); The secondary aim is the analyses of the modification of the quality of life, mood, behavioral disturbances, and physical function in people with mild-stage Alzheimer's disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer Disease
Keywords
Alzheimer Disease, virtual system, aerobic exercise, cognitive training, dementia, quality of life

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
78 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
JDome rehabilitation group
Arm Type
Experimental
Arm Description
Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with the JDome System
Arm Title
control group
Arm Type
Active Comparator
Arm Description
Patients will undergo cognitive training with Brainer web platform via tablet followed by aerobic exercise with standard exercise bike
Intervention Type
Device
Intervention Name(s)
Computerized cognitive training plus aerobic exercise with the JDome System
Intervention Description
Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks). Each session will involve the following activities: 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia 30 minutes of aerobic training with the JDOME system,
Intervention Type
Device
Intervention Name(s)
Computerized cognitive training plus aerobic exercise with standard exercise bike
Intervention Description
Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks). Each session will involve the following activities: 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia 30 minutes of aerobic training with standard exercise bike
Primary Outcome Measure Information:
Title
change in cognitive impairment
Description
Mini-Mental State Examination was designed as a clinical method for grading cognitive impairment. The score ranges from 0 to 30: scores ≥ 24 indicate normality, between 18-23 indicate mild cognitive impairment, between 11-17 moderate cognitive deficits, scores ≤ 10 severe cognitive impairments. The reported score will be corrected according to age and education.
Time Frame
baseline, 8, and 22 weeks later
Title
change in short and medium term memory
Description
Alzheimer's Disease Assessment Scale (ADAS-cog) consists of 11 items that investigate: short and medium term memory, language, praxia (simple, constructive, ideational), temporal-spatial orientation. The score ranges from 0 (no cognitive impairment) to 70 (maximum cognitive impairment).
Time Frame
baseline, 8 and 22 weeks later
Secondary Outcome Measure Information:
Title
change in quality of life
Description
Alzheimer's Disease scale (QoL-AD) includes 13 items that evaluate subjective (eg, perceived quality of life and psychological well-being) and objective (eg, behavioral competence and environment) components of the quality of life. Items are rated by subjects with dementia on a 4-point scale from 1 (poor) to 4 (excellent). Higher scores indicate a better quality of life.
Time Frame
baseline and 8, 22 weeks later
Title
change in physical performance
Description
Short Physical Performance Battery (SPPB) is a short battery of tests designed to assess the function of the lower limbs. This scale consists of 3 different sections: balance assessment, evaluation of walking on 4 linear meters, evaluation of the ability to perform, for 5 consecutive times, the sit to stand from a chair, without using the upper limbs. The total scale score therefore has a range from 0 to 12. A total score below 10 indicates frailty and a high risk of disability and falls. The 1-point change in score from pre to post test is of clinical relevance.
Time Frame
baseline, 8 and 22 weeks later
Title
change in signs and symptoms of major depression
Description
Cornell Scale for Depression in dementia (CSDD) contains 19 items evaluating signs and symptoms of major depression in individuals with dementia. Each item is rated for severity on a scale from 0 (absent) to 2 (severe). The information is collected through clinical observation and through two semi-structured interviews: one addressed to the caregiver and one to the person with dementia. The total score, given by the sum of the 19 items, if lower than 6 indicates the absence of depressive symptoms, if higher than 10 it indicates a probable major depression and finally if higher than 18 it indicates the presence of major depression
Time Frame
baseline, 8 and 22 weeks later
Title
change in neuropsychiatric disturbances
Description
Neuropsychiatric Inventory (NPI) evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, night-time behavior disturbances, and appetite and eating abnormalities. A total NPI score and a total caregiver distress score are calculated. The total NPI score, which can range from 1 to 144, is the product of the frequency of manifestation and the severity of each disorder. Higher scores indicate more frequent and more severe behavioral problems
Time Frame
baseline, 8 and 22 weeks later

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 65 and over; Pre-existing diagnosis of Alzheimer's, in mild phase, according to the 2011 criteria of the National Institute on Aging-Alzheimer's Association (NIA-AA); Clinical Dementia Rating Scale CDR = 1; Mini Mental State Examination MMSE > 19; Functional Ambulation Categories FAC ≥4; Tinetti scale ≥ 20; Presence of a contact family caregiver Reside at home Exclusion Criteria: Failure to meet the inclusion criteria Sensory deficits not compensated by the use of prostheses Psychological and behavioral disorders not compensated by drug treatment Medical contraindication to moderate intensity aerobic exercise
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Anna Rita Bonfigli
Phone
+390718003719
Email
a.bonfigli@inrca.it
First Name & Middle Initial & Last Name or Official Title & Degree
Elvira Maranesi
Email
e.maranesi@inrca.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giuseppe Pelliccioni, MD
Organizational Affiliation
IRCCS INRCA, Ancona, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cognitive Disorders and Dementia (CDCD) -INRCA Hospital
City
Ancona
ZIP/Postal Code
60127
Country
Italy
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Patrizia Civerchia
Email
p.civerchia@inrca.it
First Name & Middle Initial & Last Name & Degree
Elena Gambella
Email
e.gambella@inrca.it

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
36034306
Citation
Gambella E, Margaritini A, Benadduci M, Rossi L, D'Ascoli P, Riccardi GR, Pasquini S, Civerchia P, Pelliccioni G, Bevilacqua R, Maranesi E. An integrated intervention of computerized cognitive training and physical exercise in virtual reality for people with Alzheimer's disease: The jDome study protocol. Front Neurol. 2022 Aug 12;13:964454. doi: 10.3389/fneur.2022.964454. eCollection 2022.
Results Reference
derived

Learn more about this trial

An Integrated Intervention of Computerized Cognitive Training and Physical Exercise in Virtual Reality for People With Alzheimer's Disease (JDome)

We'll reach out to this number within 24 hrs